Targeted rapid degradation of bilirubin has the potential to thwart incipient bilirubin encephalopathy. We investigated a novel spinel-structured citrate-functionalized trimanganese tetroxide nanoparticle (C-Mn3O4 NP, the nanodrug) to degrade both systemic and neural bilirubin loads.
Severe neonatal unconjugated hyperbilirubinemia (SNH) was induced in neonatal C57BL/6j mice model with phenylhydrazine (PHz) intoxication. Efficiency of the nanodrug on both in vivo bilirubin degradation and amelioration of bilirubin encephalopathy and associated neurobehavioral sequelae were evaluated.
Single oral dose (0.25 mg kg−1 bodyweight) of the nanodrug reduced both total serum bilirubin (TSB) and unconjugated bilirubin (UCB) in SNH rodents. Significant (p < 0.0001) UCB and TSB-degradation rates were reported within 4–8 h at 1.84 ± 0.26 and 2.19 ± 0.31 mg dL−1 h−1, respectively. Neural bilirubin load was decreased by 5.6 nmol g−1 (p = 0.0002) along with improved measures of neurobehavior, neuromotor movements, learning, and memory. Histopathological studies confirm that the nanodrug prevented neural cell reduction in Purkinje and substantia nigra regions, eosinophilic neurons, spongiosis, and cell shrinkage in SNH brain parenchyma. Brain oxidative status was maintained in nanodrug-treated SNH cohort. Pharmacokinetic data corroborated the bilirubin degradation rate with plasma nanodrug concentrations.
This study demonstrates the in vivo capacity of this novel nanodrug to reduce systemic and neural bilirubin load and reverse bilirubin-induced neurotoxicity. Further compilation of a drug-safety-dossier is warranted to translate this novel therapeutic chemopreventive approach to clinical settings.
None of the current pharmacotherapeutics treat severe neonatal hyperbilirubinemia (SNH) to prevent risks of neurotoxicity.
In this preclinical study, a newly investigated nano-formulation, citrate-functionalized Mn3O4 nanoparticles (C-Mn3O4 NPs), exhibits bilirubin reduction properties in rodents.
Chemopreventive properties of this nano-formulation demonstrate an efficacious, efficient agent that appears to be safe in these early studies.
Translation of C-Mn3O4 NPs to prospective preclinical and clinical trials in appropriate in vivo models should be explored as a potential novel pharmacotherapy for SNH.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
All data that support the findings of this study are available within the published article. Study-related additional data will be available from S.K.P. upon legitimate request.
Bhutani, V. K. & Stevenson, D. K. The need for technologies to prevent bilirubin-induced neurologic dysfunction syndrome. Semin. Perinatol. 35, 97–100 (2011).
Slusher, T. M., Zipursky, A. & Bhutani, V. K. A global need for affordable neonatal jaundice technologies. Semin. Perinatol. 35, 185–191 (2011).
Bhutani, V. K. et al. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J. Perinatol. 36, 533–539 (2016).
Qattea, I., Farghaly, M. A. A., Elgendy, M., Mohamed, M. A. & Aly, H. Neonatal hyperbilirubinemia and bilirubin neurotoxicity in hospitalized neonates: analysis of the US database. Pediatr. Res. (2021).
Olusanya, B. O., Teeple, S. & Kassebaum, N. J. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 Study. Pediatrics 141, e20171471 (2018).
Fujiwara, R., Nguyen, N., Chen, S. & Tukey, R. H. Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc. Natl Acad. Sci. USA 107, 5024 (2010).
Bhutani, V. K. et al. Neonatal hyperbilirubinemia and rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr. Res. 74, 86–100 (2013).
Dandona, R. et al. Subnational mapping of under-5 and neonatal mortality trends in India: The Global Burden of Disease Study 2000–17. Lancet 395, 1640–1658 (2020).
Valaes, T., Petmezaki, S., Henschke, C., Drummond, G. S. & Kappas, A. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics 93, 1–11 (1994).
Wong, R. J., Bhutani, V. K., Vreman, H. J. & Stevenson, D. K. Pharmacology review: tin mesoporphyrin for the prevention of severe neonatal hyperbilirubinemia. NeoReviews 8, e77–e84 (2007).
Reddy, P., Najundaswamy, S., Mehta, R., Petrova, A. & Hegyi, T. Tin-mesoporphyrin in the treatment of severe hyperbilirubinemia in a very-low-birth-weight infant. J. Perinatol. 23, 507–508 (2003).
Dennery, P. A. Metalloporphyrins for the treatment of neonatal jaundice. Curr. Opin. Pediatr. 17, 167–169 (2005).
Drummond, G. S. & Kappas, A. Chemoprevention of severe neonatal hyperbilirubinemia. Semin. Perinatol. 28, 365–368 (2004).
FDA Pediatric Advisory Committee. FDA Advisory Committee Briefing Document: Stannsoporfin for the Treatment of Neonatal Hyperbilirubinemia 1–162 (United States Food and Drug Administration (US-FDA), MD, USA, 2018).
Kinnear, C., Moore, T. L., Rodriguez-Lorenzo, L., Rothen-Rutishauser, B. & Petri-Fink, A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem. Rev. 117, 11476–11521 (2017).
Pelaz, B. et al. Diverse applications of nanomedicine. ACS Nano 11, 2313–2381 (2017).
Walkey, C. D. & Chan, W. C. W. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780–2799 (2012).
Wagner, V., Dullaart, A., Bock, A.-K. & Zweck, A. The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211–1217 (2006).
Doshi, N. & Mitragotri, S. Designer biomaterials for nanomedicine. Adv. Funct. Mater. 19, 3843–3854 (2009).
de Lázaro, I. & Mooney, D. J. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat. Mater. 20, 1469–1479 (2021).
Barenholz, Y. C. In Handbook of Harnessing Biomaterials in Nanomedicine (ed. Peer, D.) 463–528 (Jenny Stanford Publishing, 2021).
United States Food and Drug Administration (US-FDA). Drug Approval Package: Abraxane (Pcalitaxel Protein-Bound Particles) Injectable Suspension. Accessed 12 Dec 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21660_AbraxaneTOC.cfm (2005).
Adhikari, A., Polley, N., Darbar, S., Bagchi, D. & Pal, S. K. Citrate functionalized Mn3O4 in nanotherapy of hepatic fibrosis by oral administration. Future Sci. OA 2, FSO146 (2016).
Adhikari, A. et al. Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice. Commun. Biol. 4, 1013 (2021).
Adhikari, A. et al. Incorporation of a biocompatible nanozyme in cellular antioxidant enzyme cascade reverses huntington’s like disorder in preclinical model. Adv. Healthc. Mater. 10, 2001736 (2021).
Adhikari, A. et al. Manganese neurotoxicity: nano-oxide compensates for ion-damage in mammals. Biomater. Sci. 7, 4491–4502 (2019).
Xu, Z. et al. Facet-dependent biodegradable Mn3O4 nanoparticles for ameliorating Parkinson’s disease. Adv. Healthc. Mater. 10, 2101316 (2021).
Aschner, J. L. & Aschner, M. Nutritional aspects of manganese homeostasis. Mol. Asp. Med. 26, 353–362 (2005).
Avila, D. S., Puntel, R. L. & Aschner, M. In Metal Ions in Life Sciences Vol. 13 (eds Sigel, A., Sigel, H. & Sigel, R. K. O.) 199–227 (Springer Netherlands, 2013).
Emsley, J. Manganese the protector. Nat. Chem. 5, 978–978 (2013).
Mattison, D. R. et al. Severity scoring of manganese health effects for categorical regression. NeuroToxicology 58, 203–216 (2017).
Li, L. & Yang, X. The essential element manganese, oxidative stress, and metabolic diseases: links and interactions. Oxid. Med. Cell. Longev. 2018, 7580707 (2018).
Mondal, S. et al. Novel one pot synthesis and spectroscopic characterization of a folate-Mn3O4 nanohybrid for potential photodynamic therapeutic application. RSC Adv. 9, 30216–30225 (2019).
Singh, N., Savanur, M. A., Srivastava, S., D’Silva, P. & Mugesh, G. A manganese oxide nanozyme prevents the oxidative damage of biomolecules without affecting the endogenous antioxidant system. Nanoscale 11, 3855–3863 (2019).
Yao, J. et al. ROS scavenging Mn3O4 nanozymes for in vivo anti-inflammation. Chem. Sci. 9, 2927–2933 (2018).
Huang, C.-C. et al. Chronic manganese intoxication. Arch. Neurol. 46, 1104–1106 (1989).
Crossgrove, J. & Zheng, W. Manganese toxicity upon overexposure. NMR Biomedicine 17, 544–553 (2004).
Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamine K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. 394–419 (Institute of Medicine (US) Washington DC, USA, 2001).
Adhikari, A. et al. Redox buffering capacity of nanomaterials as an index of ROS-based therapeutics and toxicity: a preclinical animal study. ACS Biomater. Sci. Eng. 7, 2475–2484 (2021).
Giri, A. et al. Unprecedented catalytic activity of Mn3O4 nanoparticles: potential lead of a sustainable therapeutic agent for hyperbilirubinemia. RSC Adv. 4, 5075–5079 (2014).
Rice, A. C. & Shapiro, S. M. A new animal model of hemolytic hyperbilirubinemia-induced bilirubin encephalopathy (kernicterus). Pediatr. Res. 64, 265–269 (2008).
Amini, N. et al. Animal kernicterus models: progress and challenges. Brain Res. 1770, 147624 (2021).
Bortolussi, G. & Muro, A. F. Experimental models assessing bilirubin neurotoxicity. Pediatr. Res. 87, 17–25 (2020).
Maity, S., Nag, N., Chatterjee, S., Adhikari, S. & Mazumder, S. Bilirubin clearance and antioxidant activities of ethanol extract of phyllanthus amarus root in phenylhydrazine-induced neonatal jaundice in mice. J. Physiol. Biochem. 69, 467–476 (2013).
Chen, S. & Tukey, R. H. Humanized UGT1 mice, regulation of UGT1A1, and the role of the intestinal tract in neonatal hyperbilirubinemia and breast milk-induced jaundice. Drug Metab. Disposition 46, 1745 (2018).
Yueh, M.-F., Chen, S., Nguyen, N. & Tukey, R. H. Developmemntal onset of bilirubin-induced neurotoxicity involves toll-like receptor-2 dependent signalling in humanized UDP-glucuronosyltransferase1 mice. J. Biol. Chem. 289, 4699–4709 (2014).
Buege, J. A. & Aust, S. D. In Methods in Enzymology Vol. 52 (eds Fleischer, S. & Packer, L.) 302–310 (Academic Press, 1978).
Adhikari, A. et al. A smart nanotherapeutic agent for in vitro and in vivo reversal of heavy-metal-induced causality: key information from optical spectroscopy. ChemMedChem 15, 420–429 (2020).
Benjamini, Y., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93, 491–507 (2006).
Adhikari, A., Mondal, S., Darbar, S. & Kumar Pal, S. Role of nanomedicine in redox mediated healing at molecular level. Biomolecular Concepts 10, 160–174 (2019).
Mondal, S. et al. Interaction of a jaundice marker molecule with a redox-modulatory nano-hybrid: a combined electrochemical and spectroscopic study toward the development of a theranostic tool. ChemMedChem e202100660 (2022).
Morgan Chan, Z. et al. Electrochemical trapping of metastable Mn3+ ions for activation of MnO2 oxygen evolution catalysts. Proc. Natl Acad. Sci. USA 115, E5261–E5268 (2018).
Polley, N. et al. Safe and symptomatic medicinal use of surface-functionalized Mn3O4 nanoparticles for hyperbilirubinemia treatment in mice. Nanomedicine 10, 2349–2363 (2015).
Organisation for Economic Co-operation and Development (OECD). Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents (2018).
Lei, S., Tang, K., Fang, Z. & Zheng, H. Ultrasonic-assisted synthesis of colloidal Mn3O4 nanoparticles at normal temperature and pressure. Cryst. Growth Des. 6, 1757–1760 (2006).
Pike, J., Hanson, J., Zhang, L. & Chan, S.-W. Synthesis and redox behavior of nanocrystalline hausmannite (Mn3O4). Chem. Mater. 19, 5609–5616 (2007).
Gagrani, A., Ding, B., Wang, Y. & Tsuzuki, T. pH dependent catalytic redox properties of Mn3O4 nanoparticles. Mater. Chem. Phys. 231, 41–47 (2019).
Shapiro, S. M. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (bind). J. Perinatol. 25, 54–59 (2005).
Cayabyab, R. & Ramanathan, R. High unbound bilirubin for age: a neurotoxin with major effects on the developing brain. Pediatr. Res. 85, 183–190 (2019).
Francis, R. O. et al. Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks. Vox Sanguinis 105, 271–282 (2013).
This study has been supported by Abdul Kalam Technology Innovation National Fellowship (INAE/121/AKF), Indian National Academy of Engineering (INAE), Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India and financial grant under BOOST scheme (339/WBBDC/1P-2/2013), Department of Biotechnology (DBT-WB), Govt. of West Bengal. M.D. received Junior Research Fellowship (JRF) from University Grants Commission (UGC), Govt. of India.
The authors declare no competing interests.
Ethics approval and consent to participate
This study does not involve human subject or clinical study. Thus, patient consent was not required. All animal studies and experimental procedures were performed at Central Animal Facility, Department of Zoology, Uluberia College, India (Reg. No.: 2057/GO/ReRcBi/S/19/CPCSEA) following the protocol approved by the Institutional Animal Ethics Committee (Ref: 02/S/UC-IAEC/01/2019) as per standard guideline of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Govt. of India.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Adhikari, A., Bhutani, V.K., Mondal, S. et al. Chemoprevention of bilirubin encephalopathy with a nanoceutical agent. Pediatr Res (2022). https://doi.org/10.1038/s41390-022-02179-5